Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT-503-3 ECT vs Eylea in Recurrent CNV Secondary to AMD
NCT02228304Phase 2Terminated
- Sponsor
- Neurotech Pharmaceuticals, Inc.
- Start
- Sep 2014
- Primary completion
- Apr 2016
- Modality
- Device-based Delivery
- Countries
- 2
01
Overview
A Phase 2 trial of NT-503-3 in age-related macular degeneration (AMD), sponsored by Neurotech Pharmaceuticals, Inc.. Started Sep 2014; status: terminated.
02
Drugs
NT-503-3
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT02228304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02228304.